跳至主要内容
临床试验/NCT03033108
NCT03033108已完成2 期

A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Kubota Vision Inc.0 个研究点目标入组 23 人开始时间: 2017年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
23
主要终点
Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram

研究概览

简要总结

This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.

详细描述

This is a multicenter, randomized, masked study to characterize the pharmacodynamics, safety and tolerability of emixustat in subjects with macular atrophy secondary to Stargardt disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Emixustat Dose 1

Experimental

lowest dose of once-daily oral emixustat

干预措施: Emixustat (Drug)

Emixustat Dose 2

Experimental

middle dose of once-daily oral emixustat

干预措施: Emixustat (Drug)

Emixustat Dose 3

Experimental

highest dose of once-daily oral emixustat

干预措施: Emixustat (Drug)

结局指标

主要结局

Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram

时间窗: Baseline and 1 month

Percent suppression compared to baseline of rod b-wave amplitude recovery after a photobleaching light.

次要结局

  • Percentage of Subjects With Adverse Events, by Severity and Seriousness(1 month)

研究者

发起方
Kubota Vision Inc.
申办方类型
Industry
责任方
Sponsor

相似试验